<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111020">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01994265</url>
  </required_header>
  <id_info>
    <org_study_id>USP/UFMG 2013</org_study_id>
    <nct_id>NCT01994265</nct_id>
  </id_info>
  <brief_title>Cognitive Impairment Related to Atrial Fibrillation Prevention Trial</brief_title>
  <acronym>GIRAF</acronym>
  <official_title>Randomized Clinical Trial for the Prevention of Cognitive Impairment in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive and functional decline observed in atrial fibrillation (AF) patients are related
      to thrombotic and/or cardioembolic events. Use of warfarin for the prevention of stroke in
      AF patients, despite effective, remains beyond desired levels because of interactions with
      food and fluctuations in blood levels. Because of a more stable anticoagulation state,
      Dabigatran may offer better protection against thrombotic phenomenon and, consequently,
      mitigate the process of cognitive and functional compromise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective parallel study including two hundred atrial fibrillation patients
      &gt; 65 years old and scoring CHADS2VASc &gt; 1. Patients will be randomized to receive Warfarin
      (INR between 2 and 3) or Dabigatran (150 mg twice daily) for two years. After one year and
      at the end of the study, individuals will be evaluated regarding cognitive endpoints
      following the National Institute of Neurological Disorders and Stroke-Canadian Stroke
      Network Vascular Cognitive Impairment Harmonization Standards (Hachinski et al. Stroke
      2006;37:2220-2241). The investigators will use the 60 minutes evaluation protocol
      complemented by the Montreal Cognitive Assessment (MoCA).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Cognitive impairment</measure>
    <time_frame>Two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cognitive impairment at two years, independently of stroke or other cerebrovascular events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with less important alteration in coagulation test as a Measure of Safety</measure>
    <time_frame>Two years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Comparison of thrombin generation test between the two treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Warfarin once daily, taken at fast, to maintain INR between 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dabigatran 150 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin once daily, at fast, targeting INR between 2 and 3</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Marevan, Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <arm_group_label>Dabigatran</arm_group_label>
    <other_name>Dabigatran 150 mg twice daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atrial fibrillation

          -  CHA2DS2-VASc Score for Atrial Fibrillation Stroke Risk (CHADS2VASc) greater than 1

        Exclusion Criteria:

          -  Heart valve disease

          -  Previous Stroke or Transient ischemic attack

          -  Cognitive impairment or any severe neurological disorder

          -  Major surgery in the last 30 days

          -  Planned elective surgery in the next three months

          -  Intracranial, ocular, spinal, retroperitoneal, or articular bleeding without trauma.

          -  Gastrointestinal bleeding in the last 12 months

          -  Symptomatic gastric ulcer

          -  Hemorrhagic disease

          -  Use of thrombolytics

          -  Uncontrolled hypertension

          -  Active cancer

          -  Contraindication for Warfarin use

          -  Reversible causes of atrial fibrillation

          -  Creatinine clearance &lt; 30 ml/min

          -  Active endocarditis

          -  Active hepatitis

          -  Severe anemia

          -  Left ventricle ejection fraction &lt; 35%
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Caramelli, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute, University of Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Caramelli, Professor</last_name>
    <phone>+551126615376</phone>
    <email>bcaramel@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adriana F Pastana</last_name>
    <phone>+551126615376</phone>
    <email>adriana.pastana@usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal Univeristy of Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paulo Caramelli, Professor</last_name>
      <email>caramelli@ufmg.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 19, 2014</lastchanged_date>
  <firstreceived_date>November 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Bruno Caramelli</investigator_full_name>
    <investigator_title>Associate Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Cognition</keyword>
  <keyword>Cognitive impairment</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Dabigatran</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Efficacy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
